---

After a PhD in Immunological Sciences at the University of Louvain, (Brussels, Belgium), Bernard Vanhove started his carreer at the Sandoz Research Institute of Vienna (Austria), working on vascular biology and xenoreactivity of human immunoglobulins. In the 90’s, he moved to the Transplantation Institute of the University of Nantes (France) and lead a research team focused on immunosuppression and immune tolerance. In 1999, he was appointed at the French National Centre for Scientific Research (CNRS) and became Research Director, working at the French National Health Institute and Medical Research (INSERM). In 2007, Bernard co-founded Effimune (now OSE Immunotherapeutics), a biotech company developing biologics in transplantation, autoimmunity and oncology, where he worked until 2018 as Chief Operating Officer. In 2019, he joined XENOTHERA as Chief Scientific and Operating Officer. He is author of more than 100 peer-reviewed publication (H-index 33) and 20 patent applications.

---